XXXX agonists in primary @entity22 and @entity308 : are they superior to sedative-hypnotics?

@entity1 @entity308 @entity73 @entity2493 @entity4911 @entity1245 @entity29050 @entity12123 @entity13498 @entity750 @entity2414 @entity734 @entity25 @entity22
Current pharmacological treatment of @entity22 involves the use of sedative-hypnotic @entity1245 and non- @entity1245 drugs. Although @entity1245 improve sleep, their multiple adverse effects hamper their application. Adverse effects include @entity2414 and cognitive functions, next-day hangover and @entity734 . Non- @entity1245 are effective for initiating sleep but are not as effective as @entity1245 for improving @entity25 or efficiency. Furthermore, their prolonged use produces adverse effects similar to those observed with @entity1245 . Inasmuch as @entity22 may be associated with decreased nocturnal @entity2493 , administration of @entity2493 is a strategy that has been increasingly used for treating @entity22 . @entity2493 can be effective for improving @entity25 without the adverse effects associated with hypnotic-sedatives. Ramelteon, a synthetic analog of @entity2493 which has a longer half life and a stronger affinity for @entity4911 , has been reportedly effective for initiating and improving sleep in both adult and elderly insomniacs without showing hangover, @entity734 , or @entity73 . @entity22 is also a major complaint among @entity1 suffering from @entity308 and is often aggravated by conventional antidepressants especially the specific @entity750 reuptake inhibitors. The novel antidepressant @entity29050 , a dual action agent with affinity for @entity2493 @entity4911 and @entity13498 receptors and 5-HT2c antagonistic properties, constitutes a new approach to the treatment of major @entity308 . @entity29050 ameliorates the symptoms of @entity308 and improves the quality and efficiency of sleep. Taken together, the evidence indicates that @entity4911 / @entity13498 receptor agonists like @entity12123 or @entity29050 may be valuable pharmacological tools for @entity22 and for @entity308 .
